NEW YORK (GenomeWeb) – Meridian Bioscience today reported its first quarter revenues fell 1 percent, due in part to continued weakness in its core diagnostics business.

For the three months ended Dec. 31, 2016, revenues fell to $46.8 million from $47.2 million a year ago, well below Wall Street analysts' average estimate of $51.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.